The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity
Open accessAbstract
OBJECTIVE—To assess long-term weight loss efficacy and safety of pramlintide used at different dosing regimens and in conjunction with lifestyle intervention (LSI). RESEARCH DESIGN AND METHODS—In a 4-month, double-blind, placebo-controlled, dose-ranging study, 411 obese subjects were randomized to receive pramlintide (six arms: 120, 240, and 360 μg b.i.d. and t.i.d.) or placebo in conjunction with a structured LSI program geared toward weight loss. Of the 4-month evaluable subjects (n = 270), 77% opted to continue preexisting treatment during an 8-month single-blind extension (LSI geared toward weight maintenance). RESULTS—At month 4, mean weight loss from baseline in the pramlintide arms ranged from 3.8 ± 0.7 to 6.1 ± 0.8 kg (2.8 ± 0.8 kg with placebo). By month 12, initial 4-month weight loss was regained in the placebo group but was maintained in all but the 120-μg b.i.d. group. Placebo-corrected weight loss with 120 μg t.i.d. and 360 μg b.i.d. averaged 3.2 ± 1.2 kg (3.1 ± 1.1% body wt) and 3.3 ± 1.1 kg (3.1 ± 1.0% body wt), respectively, at month 4 (both P < 0.01; 4-month evaluable n = 270) and 6.1 ± 2.1 kg (5.6 ± 2.1% body wt) and 7.2 ± 2.3 kg (6.8 ± 2.3% body wt), respectively, at month 12 (both P < 0.01; 12-month evaluable n = 146). At month 12, 40 and 43% of subjects treated with 120 μg t.i.d. and 360 μg b.i.d., respectively, achieved ≥10% weight loss (vs. 12% for placebo). Nausea, the most common adverse event with pramlintide in the 4-month study (9–29% pramlintide vs. 2% placebo), was generally mild to moderate and occurred in <10% of subjects during the extension. CONCLUSIONS—When used over 12 months as an adjunct to LSI, pramlintide treatment, with low-dose three-times-daily or higher-dose two-times-daily regimens, helped obese subjects achieve greater initial weight loss and enhanced long-term maintenance of weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pramlintide is the first synthetic amylin analogue that approved for diabetes management with WL up to 7.9% [86].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [86]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, the pramlintide 120 lg three times daily group demonstrated a significant placebocorrected 4.6-mm Hg reduction in SBP and a trend toward improvement with a placebo-corrected 2.6-mm Hg decrease in DBP.”
From Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of The Obesity Society and the American Society of Hypertension (2013) · cites this paper as [215]
In the citing paper
“In one study, 215 placebo-corrected weight loss at month 12 for the pramlintide 120 lg three times daily group averaged 6.1 kg, with higher doses providing little additional benefit.”
From Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of The Obesity Society and the American Society of Hypertension (2013) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · PubMed · Cited by 13,173
Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity
Wadden, T. A., Berkowitz, R. I., Womble, L. G., Sarwer, D. B., Phelan, S., Cato, R. K., Hesson, L. A., Osei, S. Y., Kaplan, R., & Stunkard, A. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050156 · Cited by 794 · cited 2×
“Although the aforementioned factors, and differences in study designs, make it difficult to contextualize pramlintide’s long-term efficacy, it is noteworthy that the proportion of subjects achieving 5 and 10% weight loss at 1 year compares quite favorably to the results reported with oral weight loss medications (15,1…”
BackgroundResultRoth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., & Baron, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706473105 · Cited by 436 · cited 1×
“In diet-induced obese rats, amylin induced synergistic, fat-specific weight loss when coadministered with leptin, a long-term adiposity signal (22).”
BackgroundSelf-citationHollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.784 · Cited by 307 · cited 1×
“This is consistent with findings from 1-year pramlintide diabetes studies, which also showed durable weight loss over 1 year (12,16,17).”
Self-citationRatner, R. E., Dickey, R., Fineman, M., Maggs, D. G., Shen, L., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01319.x · Cited by 307 · cited 1×
“This is consistent with findings from 1-year pramlintide diabetes studies, which also showed durable weight loss over 1 year (12,16,17).”
Self-citationEffect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes
Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1732-4 · Cited by 205
Self-citationAronne, L., Fujioka, K., Aroda, V., Chen, K., Halseth, A., Kesty, N. C., Burns, C., Lush, C. W., & Weyer, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2003 · Cited by 178 · cited 1×
“vious studies (9), pramlintide-mediated weight loss was clearly dissociable from the occurrence of nausea.”
BackgroundSelf-citationRoth, J. D., Hughes, H., Kendall, E., Baron, A. D., & Anderson, C. M. (2006) · Endocrinology · doi:10.1210/en.2006-0393 · Cited by 171
Anorectics on Trial: A Half Century of Federal Regulation of Prescription Appetite Suppressants
Colman, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-5-200509060-00013 · Cited by 167 · cited 2×
“To date, efforts to develop obesity pharmacotherapies aimed at reducing food intake and body weight have largely focused on smallmolecule anorectics, an approach that has repeatedly been hampered by safety concerns (1).”
BackgroundSmith, I. G., & Goulder, M. A. (2001) · PubMed · Cited by 149
Smith, S. R., Blundell, J. E., Burns, C. M., Ellero, C., Schroeder, B. E., Kesty, N. C., Chen, K. S., Halseth, A. E., Lush, C. W., & Weyer, C. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00217.2007 · Cited by 134
Self-citationPancreatic Amylin as a Centrally Acting Satiating Hormone
Lutz, T. A. (2005) · Current Drug Targets · doi:10.2174/1389450053174596 · Cited by 122
Mack, C. M., Wilson, J., Athanacio, J., Reynolds, J. M., Laugero, K., Guss, S., Vu, C., Roth, J., & Parkes, D. (2007) · American Journal of Physiology. Regulatory Integrative and Comparative Physiology · doi:10.1152/ajpregu.00297.2007 · Cited by 115
Handbook of Obesity: Clinical Applications
Bray, G. A., & Bouchard, C. (2003) · Cited by 101
Kruger, D. F., & Gloster, M. (2004) · Drugs · doi:10.2165/00003495-200464130-00003 · Cited by 78
Obesity Research—Limitations of Methods, Measurements, and Medications
Simons-Morton, D. G. (2006) · JAMA · doi:10.1001/jama.295.7.826 · Cited by 70 · cited 1×
“These include a relatively high attrition rate, a common, well-recognized problem in obesity pharmacotherapy studies (18), and the possibility of selfselection bias.”
Guidance for the Clinical Evaluation of Weight-Control Drugs
(2001) · Critical Reviews in Food Science and Nutrition · doi:10.1080/20014091091760 · Cited by 32
Chen, H. C., Roth, J. D., Schroeder, B. E., & Weyer, C. (2008) · Current Diabetes Reviews · doi:10.2174/157339908784220741 · Cited by 19
Self-citationRoth, J. D., Mack, C. M., Parkes, D. G., Kesty, N. C., & Weyer, C. (2008) · CRC Press eBooks · doi:10.3109/9781420051452-22 · Cited by 4
Self-citation
Research works printed but not linked: 1
- National Institutes of Health: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report [article online], 1998 (NIH publ. no. 98-4083). Available from http://www.ncbi.nlm.nih.gov/books/bookres.fcgi/obesity/obesity.pdf. Accessed 8 December 2005
Cited by
Landsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd‐Jones, D., & Sowers, J. (2013) · The Journal of Clinical Hypertension · doi:10.1111/jch.12049 · Cited by 528
Self-citationAmylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
“Pramlintide was evaluated in conjunction with lifestyle intervention in a phase 2b dose-ranging proof-of-concept study (Smith et al., 2008).”
BackgroundMethodInfluentialRavussin, E., Smith, S. R., Mitchell, J. A., Shringarpure, R., Shan, K., Maier, H., Koda, J. E., & Weyer, C. (2009) · Obesity · doi:10.1038/oby.2009.184 · Cited by 332
Self-citationWhat is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“Pramlintide is the fi rst synthetic amylin analogue that approved for diabetes management with WL up to 7.9% [86].”
InfluentialLandsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd‐Jones, D., & Sowers, J. (2013) · Obesity · doi:10.1002/oby.20181 · Cited by 284
Self-citation
Metadata
- Authors
- Smith, S. R., Aronne, L. J., Burns, C. M., Kesty, N. C., Halseth, A. E., & Weyer, C.
- Affiliations
- Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana
- Weill Cornell Medicine (US)
- Amylin Pharmaceuticals, San Diego, California
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2008-09-01
- Volume
- 31
- Issue
- 9
- Pages
- 1816-1823
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2518351
- OpenAlex
- W2170571946
- Cited by
- 172
- References
- 19
- Citations by year
- 2026: 11 · 2025: 17 · 2024: 5 · 2023: 5 · 2022: 4 · 2021: 15 · 2020: 6 · 2019: 4 · 2018: 6 · 2017: 6 · 2016: 8 · 2015: 6 · 2014: 3 · 2013: 11 · 2012: 16
- FWCI
- 10.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- European Foundation for the Study of Diabetes
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- pramlintide, obesity, weight loss, lifestyle intervention, GLP-1 receptor agonists, dose-ranging, weight maintenance, nausea, adverse events, long-term efficacy, weight regain
- MeSH terms
- Adult, Amyloid, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Life Style, Male, Middle Aged, Placebos, Time Factors, Weight Loss, Body Mass Index, Single-Blind Method, Body Size, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.